283 related articles for article (PubMed ID: 1913520)
21. Placental alkaline phosphatase and cancer antigen 125 in sera of patients with benign and malignant diseases.
Eerdekens MW; Nouwen EJ; Pollet DE; Briers TW; De Broe ME
Clin Chem; 1985 May; 31(5):687-90. PubMed ID: 3857128
[TBL] [Abstract][Full Text] [Related]
22. A new immunoassay using monoclonal antibodies HMFG1 and HMFG2 together with an existing marker CA125 for the serological detection and management of epithelial ovarian cancer.
Dhokia B; Canney PA; Pectasides D; Munro AJ; Moore M; Wilkinson PM; Self C; Epenetos AA
Br J Cancer; 1986 Dec; 54(6):891-5. PubMed ID: 3467785
[TBL] [Abstract][Full Text] [Related]
23. Comparison of three tumor markers--CA-125, lipid-associated sialic acid (LSA), and NB/70K--in monitoring ovarian cancer.
Petru E; Sevin BU; Averette HE; Koechli OR; Perras JP; Hilsenbeck S
Gynecol Oncol; 1990 Aug; 38(2):181-6. PubMed ID: 2387533
[TBL] [Abstract][Full Text] [Related]
24. CA 15-3 serum levels in ovarian cancer.
Scambia G; Benedetti Panici P; Baiocchi G; Perrone L; Greggi S; Di Roberto P; Mancuso S
Oncology; 1988; 45(3):263-7. PubMed ID: 3163419
[TBL] [Abstract][Full Text] [Related]
25. Combining CA 125 and SMR serum markers for diagnosis and early detection of ovarian carcinoma.
McIntosh MW; Drescher C; Karlan B; Scholler N; Urban N; Hellstrom KE; Hellstrom I
Gynecol Oncol; 2004 Oct; 95(1):9-15. PubMed ID: 15385104
[TBL] [Abstract][Full Text] [Related]
26. Expression of CEA, CA125, CA19-9 and human milk fat globule membrane antigen in ovarian tumours.
Macdonald F; Bird R; Stokes H; Russell B; Crocker J
J Clin Pathol; 1988 Mar; 41(3):260-4. PubMed ID: 3162916
[TBL] [Abstract][Full Text] [Related]
27. CA 72-4 radioimmunoassay in the diagnosis of malignant effusions. Comparison of various tumor markers.
Ferroni P; Szpak C; Greiner JW; Simpson JF; Guadagni F; Johnston WW; Colcher D
Int J Cancer; 1990 Sep; 46(3):445-51. PubMed ID: 2394511
[TBL] [Abstract][Full Text] [Related]
28. Ovarian cancer screening. The use of serial complementary tumor markers to improve sensitivity and specificity for early detection.
Berek JS; Bast RC
Cancer; 1995 Nov; 76(10 Suppl):2092-6. PubMed ID: 8635006
[TBL] [Abstract][Full Text] [Related]
29. Clinical evaluation of circulating serum sialyl Tn antigen levels in patients with epithelial ovarian cancer.
Kobayashi H; Terao T; Kawashima Y
J Clin Oncol; 1991 Jun; 9(6):983-7. PubMed ID: 1851822
[TBL] [Abstract][Full Text] [Related]
30. Serum placental-like alkaline phosphatase (PLAP): a novel combined enzyme linked immunoassay for monitoring ovarian cancer.
Fisken J; Leonard RC; Shaw G; Bowman A; Roulston JE
J Clin Pathol; 1989 Jan; 42(1):40-5. PubMed ID: 2921344
[TBL] [Abstract][Full Text] [Related]
31. OVX1 radioimmunoassay complements CA-125 for predicting the presence of residual ovarian carcinoma at second-look surgical surveillance procedures.
Xu FJ; Yu YH; Daly L; DeSombre K; Anselmino L; Hass GM; Berchuck A; Soper JT; Clarke-Pearson DL; Boyer C
J Clin Oncol; 1993 Aug; 11(8):1506-10. PubMed ID: 8336189
[TBL] [Abstract][Full Text] [Related]
32. CA 125, placental alkaline phosphatase, and tissue polypeptide antigen in the monitoring of ovarian carcinoma. A comparative study of three different tumor markers.
Hørding U; Toftager-Larsen K; Dreisler A; Lund B; Daugaard S; Lundvall F; Arends J; Winkel P; Rørth M
Gynecol Obstet Invest; 1990; 30(3):178-83. PubMed ID: 2265805
[TBL] [Abstract][Full Text] [Related]
33. Serum placental alkaline phosphatase (PLAP) in gynecologic malignancies--with special reference to the combination of PLAP and CA54/61 assay.
Nozawa S; Udagawa Y; Ohkura H; Negishi Y; Akiya K; Inaba N; Takamizawa H; Kimura E; Terashima Y
Clin Chim Acta; 1990 Jan; 186(2):275-84. PubMed ID: 2178810
[TBL] [Abstract][Full Text] [Related]
34. Preoperative evaluation of serum CA 125, TAG 72, and CA 15-3 in patients with endometrial carcinoma.
Soper JT; Berchuck A; Olt GJ; Soisson AP; Clarke-Pearson DL; Bast RC
Am J Obstet Gynecol; 1990 Oct; 163(4 Pt 1):1204-9. PubMed ID: 2220931
[TBL] [Abstract][Full Text] [Related]
35. [Value of the TAG-72 (CA 72-4) tumor marker in primary diagnosis of ovarian carcinoma. A comparison with the established CA-125 marker].
Zeimet AG; Guadagni F; Marth C; Amato T; Müller-Holzner E; Huter O; Daxenbichler G; Dapunt O
Geburtshilfe Frauenheilkd; 1995 Apr; 55(4):195-9. PubMed ID: 7789707
[TBL] [Abstract][Full Text] [Related]
36. Immunosuppressive acidic protein and CA 125 levels in patients with ovarian cancer.
Castelli M; Battaglia F; Scambia G; Panici PB; Ferrandina G; Mileo AM; Mancuso S; Ferrini U
Oncology; 1991; 48(1):13-7. PubMed ID: 1987493
[TBL] [Abstract][Full Text] [Related]
37. Urinary mesothelin provides greater sensitivity for early stage ovarian cancer than serum mesothelin, urinary hCG free beta subunit and urinary hCG beta core fragment.
Badgwell D; Lu Z; Cole L; Fritsche H; Atkinson EN; Somers E; Allard J; Moore RG; Lu KH; Bast RC
Gynecol Oncol; 2007 Sep; 106(3):490-7. PubMed ID: 17532030
[TBL] [Abstract][Full Text] [Related]
38. Sialyl-Tn, sialyl-Lewis Xi, CA 19-9, CA 125, carcinoembryonic antigen, and tissue polypeptide antigen in differentiating ovarian cancer from benign tumors.
Inoue M; Fujita M; Nakazawa A; Ogawa H; Tanizawa O
Obstet Gynecol; 1992 Mar; 79(3):434-40. PubMed ID: 1346716
[TBL] [Abstract][Full Text] [Related]
39. Clinical evaluation of serum sialosyl-Tn antigen levels in comparison with CA 125 levels in gynecologic cancers.
Ryuko K; Iwanari O; Nakayama S; Iida K; Kitao M
Cancer; 1992 May; 69(9):2368-78. PubMed ID: 1562985
[TBL] [Abstract][Full Text] [Related]
40. The ovarian-carcinoma-associated sebaceous gland antigen is a member of the HMFG2-positive family of epithelial mucins.
de Kretser T
Tumour Biol; 1988; 9(2-3):154-64. PubMed ID: 2456600
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
